Moderna: promising results for new Covid vaccine

(CercleFinance.com) - Moderna today announced that mRNA-1283, its next-generation Covid-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2.
compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine.

It is delighted to announce its fourth infectious disease vaccine program with positive Phase 3 data, validating our robust mRNA platform.

mRNA-1283 is an essential component of our combined COVID-19 and influenza vaccine, mRNA-1083, and this milestone gives us confidence in our ability to bring this much-needed vaccine to market, it added.


Copyright (c) 2024 CercleFinance.com. All rights reserved.